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Background:  Pathogenic  bacteria  are  often  asymptomatically  carried  in the  nasopharynx.  Bacterial  car-
riage can be  reduced  by  vaccination  and  has  been  used  as an  alternative  endpoint  to  clinical  disease  in
randomised  controlled  trials  (RCTs).  Vaccine  efﬁcacy  (VE) is usually  calculated  as 1 minus a measure  of
effect.  Estimates  of  vaccine  efﬁcacy  from  cross-sectional  carriage  data  collected  in  RCTs  are  usually  based
on prevalence  odds  ratios (PORs)  and  prevalence  ratios  (PRs),  but  it is  unclear  when  these  should  be
measured.
Methods:  We  developed  dynamic  compartmental  transmission  models  simulating  RCTs  of  a  vaccine
against  a  carried  pathogen  to investigate  how  VE can  best  be estimated  from  cross-sectional  carriage  data,
at which  time  carriage  should  optimally  be  assessed,  and  to  which  factors  this  timing  is most  sensitive.
In  the  models,  vaccine  could  change  carriage  acquisition  and  clearance  rates  (leaky  vaccine);  values  for
these effects  were  explicitly  deﬁned  (facq, 1/fdur).  POR  and PR were  calculated  from  model  outputs.  Models
differed  in infection  source:  other  participants  or  external  sources  unaffected  by  the  trial.  Simulations
using  multiple  vaccine  doses  were  compared  to  empirical  data.
Results:  The  combined  VE  against  acquisition  and  duration  calculated  using  POR  (V̂Eacq.dur , (1 − POR)  ×  100)
best  estimates  the  true  VE (VEacq.dur , (1 − facq ×  fdur)  ×  100)  for  leaky  vaccines  in  most  scenarios.  The  mean
duration  of  carriage  was  the  most  important  factor  determining  the  time  until V̂Eacq.dur ﬁrst  approximates
VEacq.dur : if the mean  duration  of  carriage  is  1–1.5 months,  up to 4 months  are  needed;  if the mean  duration
is 2–3 months,  up  to  8 months  are needed.  Minor  differences  were  seen  between  models  with  different
infection  sources.  In  RCTs  with  shorter  intervals  between  vaccine  doses  it takes  longer  after  the  last  dose
until V̂Eacq.dur approximates  VEacq.dur .
Conclusion:  The  timing  of sample  collection  should  be  considered  when  interpreting  vaccine  efﬁcacy
against  bacterial  carriage  measured  in RCTs.
ublis©  2014  The  Authors.  P
. Introduction
The estimation of vaccine efﬁcacy (VE) from randomised con-
rolled trials (RCTs) is complex because vaccines can act on different
tages of the infection dynamics and disease, and because vac-
ination itself can affect the transmission of disease in the trial
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population (Smith et al., 1984; Halloran et al., 1997, 1999). Much
has been published about complexities in the estimation of VE
against clinical disease (Smith et al., 1984; Halloran and Struchiner,
1995; Halloran et al., 1997, 1999), but less information is avail-
able for other outcomes such as asymptomatic colonisation of the
nasopharynx by bacterial pathogens. Asymptomatic colonisation,
or carriage, is often measured in RCTs of vaccines that aim to pre-
vent disease caused by bacterial pathogens because carriage is a
more common outcome than clinical disease and efﬁcacy of vaccine
against clinical disease can be mediated through carriage (Simell
et al., 2012). Examples of such pathogens and vaccines include
Streptococcus pneumoniae and pneumococcal conjugate vaccines
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Table  1
Model parameters describing the transmission of the pathogen, and the extent and effect of vaccination.
Parameter Description Baseline value Sensitivity analyses
(uni- and multivariate)
Restricted multivariate
sensitivity analysis
Sensitivity analysis on
steady state
assumption
Multiple doses
of vaccines
Model
validation
Baseline and
constant FOI
models
Baseline and constant
FOI models
Baseline and constant
FOI models
Baseline and constant
FOI models
Baseline model Constant FOI
model
Carriage parameters
1/  Mean duration of
carriage in the absence
of vaccination ( ,
carriage clearance rate)
1.25ma 1 day–12mb 1 day–12mb 1.25ma 1.25ma 5d, 1.25m
4.3mc
PB Equilibrium prevalence
of carriage in the
absence of vaccination
0.25a 0.001–0.99 0.001-0.5d 0.001–0.99 0.25a VT 0.32e
VT + 6A 0.37e
Pinit Prevalence at the start
of the model run
Steady state
(Pinit = PB)
Steady state (Pinit = PB) Steady state (Pinit = PB) 0.001–0.99 Steady state
(Pinit = PB)
VT 0.15f
VT + 6A 0.18f
 ˇ Transmission
parameter, /(1−PB)
1.07 g Changes with  and PB Changes with  and PB Changes with  and PB Changes with 
and PB
Changes with 
and PB
Vaccine parameters
VEacq Vaccine efﬁcacy against
acquisition of carriage,
(1 − facq) × 100
60% 0–99% 0–99% 60% See Table 2 See Table 3
VEdur Vaccine efﬁcacy against
duration of carriage,
(1 − fdur ) × 100
0% 0–99% 0–20%h 0% See Table 2 See Table 3
VEacq.dur Vaccine efﬁcacy
against acquisition and
duration of carriage
(1 − (facq × fdur )) × 100
60% Calculated from
facq and fdur
Calculated from
facq and fdur
60% Calculated
from
facq and fdur
Calculated
from
facq and fdur
q Proportion vaccinated
in the trial population
0.33 0.01–0.99 0.1–0.6 0.33 0.33 0.33 vaccinated
with each
schedule
FOI – force of infection; m – months; VT – 7-valent pneumococcal conjugate vaccine serotypes.
a Based on combined estimate for all 7-valent PCV serotypes in 3–59 month olds in Kenya (Abdullahi et al., 2012). Other studies in Denmark, Finland and the United
Kingdom did not provide prevalence or duration of carriage data for 7-valent PCV serotypes separately, but duration of carriage for all serotypes combined or individual
serotypes were generally similar or longer than in the Kenya data (Auranen et al., 2000, 2010; Raymond et al., 2001; Melegaro et al., 2004).
b Range explored in sensitivity analysis reﬂects a very short duration (1 day) and the longest estimates for the carriage of pneumococcus, Haemophilus inﬂuenzae type b
and  Neisseria meningitidis (Auranen et al., 1996; Trotter et al., 2006; Abdullahi et al., 2012).
c Based on data for 7-valent PCV serotypes in 3–59 month olds in Kenya (Abdullahi et al., 2012). The minimum lower bound for the conﬁdence interval around the mean
duration of carriage for any vaccine serotype was  5 days, and the maximum upper bound for the conﬁdence interval around the mean duration of carriage for any vaccine
serotype was  130 days.
d Carriage prevalence is generally below 50% although it can be higher in some populations (Simell et al., 2012).
e Maximum prevalence amongst randomised unvaccinated individuals in the Israeli trial (calculated from individual patient data). These maximums occurred at 12 months
of  age (Dagan et al., 2012).
f Prevalence amongst randomised unvaccinated individuals in the Israeli trial at 2 months of age (calculated from individual patient data). In simulations, model runs were
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g The baseline value for  ˇ is calculated from the baseline values of  and PB .
h Conjugate vaccines have not been observed to have a marked effect on duration
PCVs) (van Gils et al., 2009; Russell et al., 2010; Ota et al., 2011;
agan et al., 2012), Haemophilus inﬂuenzae type B (Hib) and Hib con-
ugate vaccines (Adegbola et al., 1998), and Neisseria meningitidis
nd meningococcal conjugate vaccines (Daugla et al., 2014).
Vaccines might affect carriage through several mechanisms
ncluding reducing susceptibility to acquiring carriage, reducing
he duration of carriage, or reducing the density of colonisation
Rinta-Kokko et al., 2009; Mina et al., 2013). In this article, the terms
Eacq and VEdur refer to the vaccine efﬁcacy against acquisition
nd duration respectively, while VEacq.dur captures the combined
fﬁcacy against acquisition and duration (Table 1). Some RCTs
ave attempted to directly estimate VEacq using longitudinal data
rom repeated nasopharyngeal samples (Dagan et al., 2003, 2012).
owever, to ensure the detection of each new acquisition and
onsequently accurately measure the underlying acquisition rate,
ampling would need to be more frequent than is feasible in most
rials. Instead, carriage is usually assessed cross-sectionally, by
ampling once or a few times after vaccination, typically starting
ne to two months after the last dose (Obaro et al., 2000; Dagan
t al., 2003; van Gils et al., 2009; Russell et al., 2010).
Vaccine efﬁcacy is usually estimated using 1 minus a measure
f effect that is expressed as a ratio. For cross-sectional carriagerriage (Barbour et al., 1995; Dagan et al., 2005; O’Brien et al., 2007).
data, possible ratio measures are prevalence odds ratios (PORs)
and prevalence ratios (PRs). The estimated VE against acquisition
and duration ( ̂VEacq.dur) in a trial can then be calculated as either
(1 − POR) × 100 or (1 − PR)  × 100. Previous studies have shown that
̂VEacq.dur calculated using the POR, once stable, can be used to esti-
mate the “true” VEacq.dur (Rinta-Kokko et al., 2009). The time until
the POR, and therefore ̂VEacq.dur , becomes stable has not been thor-
oughly investigated (Auranen et al., 2013a) either for when single
doses or for when multiple doses of vaccine are given in a vaccine
schedule. Previous methods have also assumed that the force of
infection (FOI) is constant during trials (Rinta-Kokko et al., 2009;
Auranen et al., 2013a,b). The assumption of a constant FOI leads
to greater analytical simplicity than allowing the FOI to change
over time but it might be an over-simpliﬁcation as it assumes that
vaccination of the trial population has no effect on the FOI.
Many groups including vaccine trial investigators, epidemi-
ologists, mathematical modellers, policy makers and systematic
reviewers need to know which ratio measure and sampling points
in time can be used to best estimate VEacq.dur . We  used a dynamic
transmission model to investigate how values of ̂VEacq.dur calcu-
lated from model outputs compared to the “true” values of VEacq.dur
used to parameterise the model. We  assessed the optimal time
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brial population respectively.  ˇ – transmission parameter; facq – acquisition rate
atio; fdur – carriage duration ratio;  – carriage clearance rate.
t which carriage should be measured, and factors to which this
iming is most sensitive. We  considered different assumptions on
ransmission, simulated trials with multiple doses of vaccine, and
alidated ﬁndings with empirical data.
. Methods
.1. Dynamic transmission model (baseline model)
We  developed a dynamic compartmental transmission model
hat simulates an RCT of a vaccine against a pathogen that can be
symptomatically carried in the nasopharynx (Fig. 1). The base-
ine model represents an unvaccinated group (X) and a group
hat receives one dose of a vaccine (V). Vaccination occurs at the
tart of each simulation, with a percentage of participants (q)
eing assigned to the vaccinated group (V). In both groups, peo-
le can either carry the pathogen (I) or are free of carriage (S). XI,
S, VI and VS represent the unvaccinated carrying, unvaccinated
on-carrying, vaccinated carrying, and vaccinated non-carrying
roportions of the trial population, N (N = XI + XS + VI + VS = 1).
nvaccinated non-carrying individuals acquire carriage at rate
(XI + VI), and after infection can clear carriage at a rate of  ,
fter which individuals become susceptible to acquiring carriage
gain. The transmission parameter, ˇ, is calculated from the equi-
ibrium prevalence of carriage in the absence of vaccination (PB)
nd  (Appendix A, Section 1.1). In the model, trial participants
cquire carriage only from other trial participants, meaning that
he FOI changes with prevalence in the trial population. The preva-
ence of carriage in the trial population is assumed to be in steady
tate at the start of the trial unless otherwise stated (PB = PInit,
here PInit is carriage prevalence at the start of the simulation).
he model is described by a set of ordinary differential equations
Appendix A, Section 1.1). The baseline values of the parame-
ers resemble those of serotypes of S. pneumoniae included in the
-valent PCV and are based on empirical data where available
Table 1).
.2. Vaccine effect
The vaccine was incorporated into the model as a leaky vaccine,
eaning that those vaccinated are still susceptible to acquiring car-
iage but at a lower rate than the unvaccinated. We explored two
ays in which a vaccine can provide protection against carriage of
 pathogen. First, the vaccine can reduce the rate at which vacci-
ated individuals acquire carriage. In the model, this is deﬁned by
acq (where facq = 1 − (trueVEacq/100)). facq is also the acquisition
ate ratio: the carriage acquisition rate in the vaccinated divided
y the carriage acquisition rate in the unvaccinated. Second, thes 9 (2014) 8–17
vaccine can reduce the mean duration of carriage. This is deﬁned by
fdur (where fdur = 1 − (trueVEdur/100)). fdur is also the carriage dura-
tion ratio: the mean duration of carriage in the vaccinated divided
by the mean duration of carriage in the unvaccinated. VEacq.dur , the
“true” combined effect of the vaccine on acquisition and carriage,
is deﬁned as (1 − facq.dur) × 100 where facq.dur = facq × fdur (Rinta-
Kokko et al., 2009). VEacq.dur can be interpreted as the percentage
reduction in time spent in the carrier state due to not acquiring
carriage, more rapid clearance, or both in the vaccinated group
when compared to the unvaccinated group. For simplicity, we
do not consider a vaccine effect on the density of colonisation
in the model. In all simulations, any effect against acquisition or
duration of carriage was assumed to commence immediately after
vaccination.
2.3. Analyses
We  ﬁrst simulated one vaccine dose using baseline values of
all parameters (Table 1). We  calculated the POR and PR at each
time step in the simulation from the proportion of the study pop-
ulation in each of the four compartments (POR = VIXS/VSXI , and
PR = (VI(XS + XI))/((VS + VI)XI)). An estimate of VEacq.dur ( ̂VEacq.dur)
was then calculated at each time step as (1 − POR) × 100 or
(1 − PR)  × 100. We plotted the ̂VEacq.dur against time and examined
whether VEacq.dur was  more closely estimated by using POR or PR.
We determined the time after vaccination at which ̂VEacq.dur ﬁrst
came within an absolute 5% of the baseline value of VEacq.dur , (i.e.
the time when ̂VEacq.dur reached 55% for the baseline VEacq.dur of
60%). We  use the term “ﬁrst approximates” throughout this article
to describe the point in time when ̂VEacq.dur reaches a value that is
a set distance below VEacq.dur .
To assess whether patterns in ̂VEacq.dur over time depend on the
mechanism of vaccine action, we explored three different scenar-
ios. In the ﬁrst scenario, the vaccine only affected the acquisition
rate (controlled by facq), with facq set at 0.4 and fdur at 1. This resulted
in facq × fdur of 0.4 and consequently a VEacq.dur of 60%. In the second
scenario, the vaccine had an effect only on the duration of carriage
(controlled by fdur), with facq set to 1 and fdur to 0.4, again resulting
in facq × fdur of 0.4 and VEacq.dur of 60%. The third scenario examined
the combined effect on duration and acquisition. The same values of
facq × fdur and VEacq.dur were maintained by setting facq at 0.6 and fdur
at 0.67. We  explored each of these scenarios for when the reproduc-
tion number after vaccination (the number of secondary infections
caused by one infected individual introduced into a hypothetical
population in which there was  previously no carriage) was above
1, where R was  exactly 1, and where R was below 1 (Appendix A,
Section 3). We  changed the value of R by setting PB to 0.25 (baseline
value), 0.2, and 0.15 respectively.
2.4. Sensitivity analysis
We  performed an analysis on the sensitivity of the time after
vaccination at which ̂VEacq.dur ﬁrst approximates the VEacq.dur to
parameter values. We deﬁned the time until ̂VEacq.dur approxi-
mated VEacq.dur to be the time until ̂VEacq.dur ﬁrst reached a value of
(11/12) × VEacq.dur . Analyses were also performed using an alter-
native deﬁnition of when ̂VEacq.dur ﬁrst came within an absolute
5% of VEacq.dur . If VEacq.dur is 60% then the value of ̂VEacq.dur to be
reached is 55% for both of these deﬁnitions. All sensitivity analy-
ses use ̂VEacq.dur based on POR, unless otherwise stated. First, using
the baseline model, we changed the parameters one at a time
over broad ranges (Table 1, fourth column). Then we performed
multivariate sensitivity analyses by creating 4000 parameter sets
through uniform sampling of parameter values over the broad
P. Scott et al. / Epidemics 9 (2014) 8–17 11
Table  2
Scenarios of vaccine effects explored for multiple doses of vaccines.
Scenario, trial Comparison VEacq , % VEdur , %
2m dose 3m dose 4m dose 6m dose All doses
Scenario 1: Each dose increases the effect on acquisition, and the extent is not affected by the age at which the dose is given
Trial 1 No doses 0 0 0 – 0
vs.
2,  3, 4m 20 40 60 – 0
Trial  2 No doses 0 – 0 0 0
vs.
2,  4, 6m 20 – 40 60 0
Scenario 2: Third dose has no additional effect, regardless of when given
Trial 1 No doses 0 0 0 – 0
vs.
2,  3, 4m 30 60 60 – 0
Trial  2 No doses 0 – 0 0 0
vs.
2,  4, 6m 30 – 60 60 0
Scenario 3: First dose has no effect
Trial 1 No doses 0 0 0 – 0
vs.
2,  3, 4m 0 30 60 – 0
Trial  2 No doses 0 – 0 0 0
vs.
2,  4, 6m 0 – 30 60 0
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anges deﬁned in Table 1. We  repeated the multivariate sensitivity
nalysis, restricting parameters to values commonly observed, or
ost likely given available evidence (Table 1, ﬁfth column).
Second, we explored the possibility that the prevalence of car-
iage in the trial population is not in steady state at the start of the
rial. We did this by ﬁrst changing the initial prevalence in the trial
opulation (Pinit) while maintaining the baseline value of the equi-
ibrium prevalence of carriage in the absence of vaccination (PB). We
hen explored whether these ﬁndings were sensitive to the equilib-
ium prevalence of carriage by performing the same analysis over
 range of values of PB.
Third, we explored the effect of the assumption in the base-
ine model of a changing FOI. We  simpliﬁed the model to the case
here the study population acquires carriage only from outside the
tudy population and vaccination in the trial does not affect car-
iage outside the study population (Appendix A, Section 1.2). These
impliﬁcations mean that the model is no longer a dynamic model
ecause the force of infection is constant over time. The model now
akes on assumptions similar to those in previous studies (Rinta-
okko et al., 2009; Auranen et al., 2013a,b). We  then performed all
nalyses and sensitivity analyses described above and compared
he results to those from the baseline model.
.5. Simulated trials with multiple doses of vaccines
To simulate more realistic trial scenarios, we extended the base-
ine model to include multiple doses of the vaccine (Appendix A,
ection 1.3). We  varied both the interval between doses and the
ffect of each dose on VEacq.dur . The unvaccinated group remained
nchanged. We  simulated two separate trials, each comparing a
ingle vaccinated group receiving three vaccine doses to an unvac-
inated (or placebo) group. The effect of each dose of vaccine did not
iffer between trials (Table 2). The trials differed only in the vaccine
chedule: 2, 3 and 4 months in trial 1 and 2, 4 and 6 months in trial
. We  explored whether the interval between doses could lead to
pparent differences in trial results even when the value of VEacq
fter the last dose was the same. We  used three scenarios for the
alue of VEacq for each dose (Table 2).2.6. Model validation: comparison with trial data
We compared patterns in outcome measures produced by the
model to empirical trial data. We  obtained individual participant
data from a 7-valent PCV trial conducted in Israel (Dagan et al.,
2012; Givon-Lavi et al., 2010 and additional data from Dagan). We
used data from three groups in the trial: a study arm that received
3 doses of the vaccine at 4, 6 and 12 months of age (two primary
doses and a booster, a 2p + 1 schedule, “schedule a”), a study arm
that received 3 doses of the vaccine at 2, 4 and 6 months (three
primary doses and no booster, a 3p + 0 schedule, “schedule b”),
and a study arm that received no vaccination until 12 months of
age (“no dose” group). Children were enrolled from health cen-
tres and were not in close contact with each other. We  therefore
used the constant FOI model for these simulations. We  adapted
the model to include the comparison between schedules in the
trial by adding a second vaccinated group (Appendix A, Section
1.4). In the model, we examined four scenarios of the effect of
vaccine on acquisition (Table 3). The values used for other param-
eters in these simulations are shown in Table 1. The system was
not assumed to be in steady state at the start of simulations. Val-
ues of Pinit were based on prevalence in the trial at 2 months of
age (when simulation runs were started), prior to vaccination. Val-
ues of PB were based on prevalence in unvaccinated individuals
in the trial at 12 months of age (Dagan et al., 2012). For both the
trial data and the model, we  compared the vaccinated groups to
the unvaccinated group and then to each other. In the model we
calculated, for each scenario, the POR for the 2p + 1 and 3p sched-
ules (compared to the unvaccinated group) and the relative POR
(RPOR, (odds(2p+1 schedule)/odds(3p schedule))). We used these values to
calculate ̂VEacq.dur and the relative ̂VEacq.dur (̂RVEacq.dur , equals (1 −
RPOR) × 100). We  then plotted these values beside the ̂VEacq.dur ,
the ̂RVEacq.dur and corresponding 95% conﬁdence intervals from
carriage data collected in the vaccine trial. We conducted these
analyses both excluding and including serotype 6A in the deﬁni-
tion of vaccine serotypes (denoted by VT and VT + 6A, respectively),
because of the potential cross-reactivity between vaccine serotype
6B and non-vaccine serotype 6A (Vakevainen et al., 2001).
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Table  3
Scenarios of vaccine effects explored in model validation.
Scenario comparison VEacq , % VEdur , %
2m dose 4m dose 6m dose 12m dose All doses
Scenario 1a: Each dose increases the effect on acquisition, and the extent is not affected by the age at which the dose is given
Trial 3 No doses 0 0 0 0 0
vs.
2,  4, 6m 20 40 60 – 0
vs.
4,  6, 12m 0 20 40 60 0
Scenario 1b: Each dose increases the effect on acquisition, and the third dose has more effect if given at 12m than if given at 6m
Trial 3 No doses 0 0 0 0 0
vs.
2,  4, 6m 20 40 60 – 0
vs.
4,  6, 12m 0 20 40 80 0
Scenario 2a: Third dose has no additional effect, regardless of when given
Trial 3 No doses 0 0 0 0 0
vs.
2,  4, 6m 30 60 60 – 0
vs.
4,  6, 12m 0 30 60 60 0
Scenario 2b: Third dose has no additional effect if given at 6m, but increases the effect on acquisition if given at 12m
Trial 3 No doses 0 0 0 0 0
vs.
2,  4, 6m 30 60 60 – 0
30 
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4,  6, 12m 0 
 – months.
ompetition between vaccine serotypes and non-vaccine serotypes
s not included in the model. We  did not ﬁt the model to the data,
ut instead examined whether predicted patterns in ̂VEacq.dur and
VEacq.dur were consistent with those in the trial data.
. Results
The estimated vaccine efﬁcacy against acquisition and dura-
ion ( ̂VEacq.dur) increases from 0% at the moment of vaccination,
owards VEacq.dur , whether calculated using POR or PR (Fig. 2). When
he vaccine only affects the acquisition of carriage (Fig. 2, panel
), the ̂VEacq.dur calculated using POR approximates the VEacq.dur
ooner than the ̂VEacq.dur calculated using PR.  The delay after vacci-
ation before the ̂VEacq.dur calculated using POR ﬁrst approximates
Eacq.dur is around three months in this scenario. The ̂VEacq.dur cal-
ulated using PR underestimates VEacq.dur for the whole trial period.
hese ﬁndings vary only slightly when R is 1 or below (Appendix B,
ig. SB1, panels D and G).
When the vaccine only has an effect on duration of carriage
Fig. 2, panel B), ̂VEacq.dur calculated using POR rapidly increases
rom 0% to an overestimate of VEacq.dur soon after vaccination. The
xtent of overestimation is small in the scenario shown (maxi-
um ̂VEacq.dur is 63% and VEacq.dur is 60%). The ̂VEacq.dur calculated
sing POR returns towards VEacq.dur if R is more than 1, but con-
inues to overestimate VEacq.dur if R is less than 1 (Fig. SB1, panel
). ̂VEacq.dur calculated using PR underestimates, equals or overes-
imates VEacq.dur depending on the value of R (Fig. SB1, panels B,
 and H, mathematical background given in Appendix A, Section
).
When the vaccine has an effect on both the acquisition and dura-
ion of carriage (Fig. 2, panel C), the results lie between those where
nly VEacq or VEdur is affected..1. Sensitivity analyses
Sensitivity analyses on model structure and parameter values
re shown in Figs. SB2–SB9. In all analyses the time until ̂VEacq.dur60 80 0
ﬁrst approximates VEacq.dur is most sensitive to the mean dura-
tion of carriage. Longer mean durations require longer times until
VEacq.dur is ﬁrst approximated (Figs. SB2 and SB2a, panels A, Fig. SB3,
panels A, B, E and F, and Figs. SB4–SB7a, panel A). For example, if the
mean duration of carriage is 1–1.5 m,  up to 4 months are needed for
the VEacq.dur to be approximated (Fig. SB6, panel A), for mean dura-
tion of 1.5–2 months up to 6 months are needed, and for a mean
duration of 2–3 months up to 8 months are needed in the baseline
model. The maximum time was around 40 months after trial start
assuming a mean duration of carriage of 11–12 m (Figs. SB4, SB4a,
SB6, SB6a, panel A). When vaccination increases the rate of clear-
ance of carriage (i.e. shortens the duration of carriage), less time is
required until ̂VEacq.dur ﬁrst approximates VEacq.dur (Figs. SB2 and
SB2a panel E, SB3 and SB3a panels D and H, and panels SB4–SB5a
panel E).
Both the baseline and constant FOI models were sensitive to the
assumptions of steady state at the trial start, but only at extreme
values. High background prevalence (PB) and low initial prevalence
in the trial population (Pinit), result in ̂VEacq.dur ﬁrst approximating
VEacq.dur rapidly (Fig. SB8). ̂VEacq.dur can overestimate VEacq.dur when
PB is markedly higher than Pinit. The extent of overestimation was
small except for at extreme values of PB and Pinit.
The constant FOI model behaves slightly differently from
the baseline model. In general the baseline model takes longer
until VEacq.dur is ﬁrst approximated by ̂VEacq.dur (Figs. SB2–SB7a),
although the difference between the models is usually small.
The overestimation of VEacq.dur when vaccine affects the dura-
tion of carriage in the baseline model is not seen in the constant
FOI model (Fig. SB10). It should be noted that the reproduc-
tion number within the trial is 0 in the constant FOI model.
This is because trial participants do not infect each other and
consequently there are no secondary infections within the trial
populationGeneral patterns observed did not change when using the alter-
native deﬁnition of when ̂VEacq.dur ﬁrst approximates VEacq.dur
( ̂VEacq.dur within an absolute 5% of VEacq.dur , Figs. SB2a, SB3a, SB4a,
SB5a, SB6a, SB7a).
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sed  except for VEacq and VEdur . The black dots indicate when values of V̂Eacq.dur rea
.2. Simulated trials comparing vaccine given as a multiple dose
chedule to no doses of vaccine
Fig. 3 shows ̂VEacq.dur for placebo controlled trials with dif-
erent intervals between doses. All scenarios shown have the
ame VEacq.dur after the last dose. In the trial with shorter inter-
als between doses, ̂VEacq.dur not surprisingly ﬁrst approximates
Eacq.dur sooner after the ﬁrst dose of vaccination than for a sched-
le with longer intervals (Fig. 3, panels A–C). Until ̂VEacq.dur becomes
table in both trials, the shorter interval schedule will appear more
ffective. This is seen regardless of assumptions about the effect of
ach dose of vaccine. If trial results are aligned at the time of last
accination (Fig. 3, panels D–F), the two month interval schedule
ill look more effective than the one month interval schedule for
 period after the last dose of vaccine in some scenarios (Fig. 3,
anel E).
.3. Model validation with trial data comparing multiple
chedules in a single trial
The patterns over time in simulated trials were consistent with
atterns in empirical data for ̂VEacq.dur for the 2p + 1 schedule
Figs. 4 and SB11, panels A–D,) and the 3p schedule (panels E–H), as
ell as for̂RVEacq.dur comparing the 2p + 1 and 3p schedules (panels
–L). Empirical data for ̂VEacq.dur were not available after 12 months
f age in the 7-valent PCV trial, when the control group received a
ose of vaccine. The point estimates for̂RVEacq.dur comparing the
p + 1 and 3p from the 7-valent PCV trial follow trends that are
ost similar to the simulations in scenarios where the third dose
f vaccine has an additional effect on carriage acquisition over the
revious two  doses (Figs. 4 and SB11, panels I and J).
There is a slow decline in̂RVEacq.dur calculated from both sim-
lated and empirical data towards a minimum value, which is
aintained until the 2p + 1 group receives the booster dose. After
his dose,̂RVEacq.dur in both simulated and empirical data change
irection and do not immediately stabilise. ThêRVEacq.dur from trial
ata become relatively stable after 19 months of age (7 months after.
the last vaccine dose) for both VT (Fig. 4, panels I–L) and VT + 6A
(Fig. SB11, panels I–L) data. In the simulated data, thêRVEacq.dur
moves to above 0% in the scenario where the booster dose at 12 m
has more effect on acquisition than a third primary dose at 6m
(Figs. 4 and SB11, panel J).
In simulations where a third dose of vaccine at 6m has no addi-
tional effect on carriage acquisition over the previous two  doses
(i.e. marginal effect of a third dose at 6m is 0, Figs. 4 and SB11, pan-
els K and L) there is a change in̂RVEacq.dur towards 0% after the 6
month dose that is not reﬂected in the trial data. The conﬁdence
intervals around the trial data are, however, wide and include the
simulated̂RVEacq.dur .
4. Discussion
Our study found that in simulated vaccine trials there is a
period after vaccination during which ̂VEacq.dur calculated using
POR will underestimate the true VEacq.dur , and that the length
of this period is most affected by the mean duration of carriage
. Overestimation of VEacq.dur occurs in some uncommon circum-
stances. In simulated trials where multiple doses of vaccine are
given, the schedule of vaccination can affect length of time dur-
ing which VEacq.dur is underestimated. Furthermore, comparisons of
multiple schedules simulated within a single trial also have periods
in whicĥRVEacq.dur (relative vaccine efﬁcacy calculated from POR)
do not reﬂect the true RVEacq.dur . The patterns predicted by the
model for such comparisons were also observed in empirical data
from a vaccine trial. This study also conﬁrms that estimates based
on POR are better than those based on PR for assessing vaccine
efﬁcacy against acquisition and duration of carriage in individually
randomised trials of leaky vaccines.
Simplicity and straightforward interpretation of outputs are
advantages of the model. Different values for the effects of a vac-
cine on carriage can be deﬁned and it can be determined when
and how best to measure these effects. Strong assumptions made
in previous investigations of the interpretation of carriage out-
comes in vaccine trials can be relaxed (Rinta-Kokko et al., 2009;
Auranen et al., 2013a,b), and changes in the estimated vaccine
14 P. Scott et al. / Epidemics 9 (2014) 8–17
A
Scenario 1: 
Each dose of vaccine increases effect
0 3 6 9 12
Time since 1st vaccination
0
10
20
30
40
50
60
70
80
Va
cc
in
e 
ef
fic
ac
y,
 %
B
Scenario 2: 
Third dose has no additional effect
0 3 6 9 12
C
Scenario 3: 
First dose has no effect
0 3 6 9 12
D
−3 0 3 6 9
Time since last vaccination
0
10
20
30
40
50
60
70
80
Va
cc
in
e 
ef
fic
ac
y,
 %
E
−3 0 3 6 9
Time since last vaccination
F
−3 0 3 6 9
Time since last vaccination
VEacq.dur Trial 1
VEacq.dur Trial 2
VEacq.dur
Time since 1st  vaccination Time since 1st  vaccination
Fig. 3. Multiple doses of vaccines, baseline model. The effect of interval between three primary vaccine doses on V̂Eacq.dur when comparing independent vaccine trials. VEacq.dur
– “true” vaccine efﬁcacy against acquisition and duration of carriage; V̂Eacq.dur – calculated vaccine efﬁcacy against acquisition and duration of carriage. Simulated results
from  two trials are shown in each panel; the black solid line shows V̂Eacq.dur for a trial comparing vaccination at 2, 3, and 4 months to no vaccination (Trial 1), and the grey
dashed line shows V̂Eacq.dur for a trial comparing vaccination at 2, 4, and 6 months to no vaccination (Trial 2). The horizontal grey line indicates VEacq.dur in both trials after 3
doses  of vaccine. The vaccine parameters used in the three scenarios are shown in Table 2. Results from simulations are the same in the upper row and the lower row except
f ch ﬁrs
p
e
e
s
m
n
f
2
u
b
(
b
t
i
c
p
n
p
b
a
t
o
c
(
r
c
that the time until ̂VE ﬁrst approximates VE is most sen-or  the alignment of trials. The vertical black dotted line indicates the point at whi
oint  at which last vaccination occurs in panels D–F.
fﬁcacy over time explicitly modelled. Nevertheless, we  made sev-
ral simplifying assumptions. The model only considered single
erotype pathogens. For pathogens such as S. pneumoniae where
ultiple serotypes compete with each other for colonisation of the
asopharynx, the calculation of the POR may  need to be adjusted
or the time of being at risk of carriage acquisition (Auranen et al.,
013b). Despite this, and the possibility of changes to the time
ntil ̂VEacq.dur measures VEacq.dur well, the conclusions about the
est estimator for calculating vaccine efﬁcacy for leaky vaccines
(1 − POR) × 100), and the presence of a delay before VEacq.dur can
e accurately measured, are likely to remain the same.
Further research should elaborate the model to incorporate mul-
iple serotypes, cluster-randomised trials and vaccines that result
n complete protection for some recipients (all-or-nothing vac-
ines), rather than partial protection for all. For example, it is
ossible that different estimators (i.e. not (1 − POR) × 100) will be
eeded for all-or-nothing vaccines, or for vaccines that completely
rotect some individuals and partially protect others. It would also
e useful to investigate whether effects of a vaccine on acquisition
nd duration of carriage can be separately estimated from mul-
iple cross-sectional samples. Previous work has examined some
f these aspects, but in these analyses a different odds ratio was
alculated to represent that used in the indirect cohort method
ratio of odds of vaccination in those carrying VT and those car-
ying non-vaccine serotypes (Omori et al., 2012). Further studies
ould incorporate an effect of vaccine on colonisation density intot vaccination occurs in panels A–C, and the vertical grey dotted line indicates the
the model. Such an effect might reduce the transmissibility of car-
riage from vaccinated individuals and increase the time required
to obtain a good estimate of vaccine efﬁcacy. However, an effect on
colonisation density could also reduce the sensitivity of nasal swab-
bing for detecting carriage, which would add additional complexity
to the estimation of vaccine efﬁcacy in trials.
In our models, we  assumed that all trial participants receive vac-
cination simultaneously and that the mean duration of carriage
remains the same over time in unvaccinated individuals. These
assumptions are also unlikely to change our conclusions, but it
is possible for confounding to occur when trial participants do
not receive vaccination simultaneously. It is also possible that a
POR calculated among those vaccinated late in the trial would take
longer to stabilise than that among those vaccinated early due to
a decreasing FOI. Last, we assumed that the effect of the vaccine
does not wane over time. This is a reasonable assumption, since we
only look at the effect of the vaccine over the time scale of a vaccine
trial.
An important message from our study is that trials of vac-
cines against pathogens with long carriage durations would need
to extend follow-up times for carriage in order to obtain accurate
estimates of VEacq.dur from cross-sectional data. Our  results showacq.dur acq.dur
sitive to the mean duration of carriage. Additionally, our models
assume that vaccine effects on carriage begin immediately after
vaccination and if this is not the case then even longer follow up
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Fig. 4. Model validation, constant FOI model. Simulations are compared with empirical data from a 7-valent PCV trial in Israel. Comparisons are made between three trial
groups. Groups receiving vaccine at 4, 6, 12 months (2p  + 1 schedule) or 2, 4, 6 months (3p schedule) are compared to a group receiving no vaccination to calculate V̂Eacq.dur and
groups  receiving vaccine at 4, 6, 12 months and 2, 4, 6 months are compared to calculate R̂VEacq.dur . A VEacq.dur of 50% can be interpreted as halving the time spent in the carrier
state  when measured over everyone in the vaccinated group compared to everyone in the unvaccinated group. The black points and vertical lines represent point estimates
and  95% conﬁdence intervals for V̂Eacq.dur and R̂VEacq.dur at each of the carriage sampling points in the trial data. The unvaccinated group in the trial received vaccination at
12m  so V̂Eacq.dur could not be calculated after this time. The parameters used in simulation of the four scenarios of vaccine effect are shown in Tables 1 and 3. Simulations
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oarriage  of 1.25m (baseline value). The outer limits of the grey band show V̂Eacq.dur
Table 3). Simulation runs started at 2m of age using values of Pinit observed in the e
alue  of 1 because no vaccinations have been given before this time. These values h
imes will be needed to accurately estimate VEacq.dur . General state-
ents about when carriage should be measured in trials cannot
e made and there can be considerable uncertainty about when
Eacq.dur should be estimated in trials of vaccines against pathogens
or which the mean duration of carriage is not well established. It is
lear, however, that unless mean duration of carriage is very short,
ross-sectional samples taken soon after vaccination are unlikely to
rovide accurate estimates of VEacq.dur . The exception to this would
e if vaccination caused rapid clearance of carriage, which would
llow estimates to be obtained faster. However, no increase in clear-
nce rate has been found for several vaccines (Barbour et al., 1995;
agan et al., 2005; O’Brien et al., 2007).
When results from several trials are being compared it should be
ecognised that low estimates of vaccine efﬁcacy against carriage
btained soon after vaccination are not necessarily inconsistent
ith higher estimates obtained more distant from vaccination.
urthermore, when deciding if it is appropriate to combine data
tatistically using meta-analysis, systematic reviewers should con-
ider whether there is any reason to believe that the mean duration
f carriage may  differ between populations in the different trialsVEacq.dur for simulations with mean durations of carriage of 5 days and 3.4 months
cal data at this age. Prior to 2m of age the simulated V̂Eacq.dur and R̂VEacq.dur take the
een added between 0 and 2m for illustrative purposes.
and whether the POR is likely to have become stable in each trial.
For S. pneumoniae, where there is variation in the mean duration of
carriage with serotype and age, as well as uncertainty around each
estimate (Abdullahi et al., 2012), both simulations and empirical
trial data suggest that̂RVEacq.dur might become stable only 7 months
after the last dose of vaccine. Several trials included in a system-
atic review of PCV took the last sample 6 months or less after the
last dose of pneumococcal vaccine (Scott et al., 2011). Mean dura-
tions of carriage for other bacterial pathogens have been estimated
to be similar to or longer than that for S. pneumoniae. The mean
duration of N. meningitidis carriage has been estimated at 3 months
for serogroup C and 9 months for other serogroups (Trotter et al.,
2006), and the mean duration of Hib carriage has been estimated
at over 5 months, depending on age (Auranen et al., 1996).
Assumptions about patterns of carriage transmission can also
affect the time until VEacq.dur is ﬁrst approximated. The baseline
model, in which carriage is acquired only from other trial partici-
pants, generally takes longer to approximate VEacq.dur than in the
constant FOI model in which trial participants are only infected
by those outside the trial. Although these scenarios represent two
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xtremes that might not occur in reality, trial settings might more
losely resemble one or the other scenario. For example, a trial
hat takes place in a day-care centre where children spend sub-
tantial amounts of time in close contact with each other more
losely resembles the baseline model and VEacq.dur might be accu-
ately measured later than in a trial where participating children
re distributed throughout the community with little direct contact
ith each other.
The ﬁndings from this study have implications for the plan-
ing and interpretation of RCTs with carriage outcomes, and for the
nterpretation of results from multiple trials. Investigators design-
ng individually randomised trials should consider explicitly when
o measure carriage after vaccination. A modelling exercise, using
vailable data to inform parameter values, could help to inform the
rocess. At a minimum, efforts should be made to obtain data about
he mean duration of carriage of the pathogen.
When synthesising the results of multiple trials, for example
n a systematic review and meta-analysis, the POR extracted from
ach trial to be used in meta-analysis should be from a time
oint after the POR has become stable. Carriage results might be
isinterpreted if VEacq.dur is estimated before the POR becomes sta-
le in all trials in a systematic review. The results of simulated
CTs in this study using vaccine schedules with different inter-
als between doses show that, even when the effect of vaccine
as been set at the same value in each trial, one schedule can
ppear better than another. Heterogeneity between trial results in
his situation might be falsely attributed to differences in VEacq.dur
ather than differences in trial design and timing of outcome
ssessment. Meta-regression or stratiﬁcation of results by timing
f outcome assessment could be used to explore heterogeneity
etween trials. There are also situations in which results across
ultiple trials appear to be consistent, but ̂VEacq.dur does not
pproximate VEacq.dur well; for example, in trials of similar design,
ut in which samples have been taken before the POR becomes
table.
In conclusion, vaccine trial investigators, policy makers, and
thers using carriage data from vaccine trials should consider the
iming of sample collection in trial design and in the interpretation
f reported vaccine efﬁcacy against carriage.
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